Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Iprazochrome→

Iprazochrome Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7248-21-7
Molecular formula
C12H16N4O3
Molecular weight
264.28 g/mol
Drug class
Indolequinone derivativeserotonin antagonist and historical antimigraine prophylactic
Mechanism of action
An adrenochrome-related indolequinone derivative with serotonin-antagonist pharmacology. It has been used to reduce serotonin-mediated vascular and platelet-related effects implicated in migraine pathophysiology; its precise mechanism and clinical relevance are not well established by modern evidence.
Indications / reported uses
  • Historically used for prophylaxis of migraine attacks in some countries; it is not a widely used contemporary first-line migraine preventive.

Sources: https://www.ncbi.nlm.nih.gov/mesh/?term=C009742 · https://pubchem.ncbi.nlm.nih.gov/#query=iprazochrome · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Iprazochrome Environmental Risk Assessment (ERA) (the Iprazochrome ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.